Long non‑coding RNA BRM promotes proliferation and invasion of papillary thyroid carcinoma by regulating the microRNA‑331‑3p/SLC25A1 axis

Liu,Shihong; Zhang,Deping; Chen,Li; Gao,Shangfang; Huang,Xiu

doi:10.3892/ol.2020.11418

Long non‑coding RNA BRM promotes proliferation and invasion of papillary thyroid carcinoma by regulating the microRNA‑331‑3p/SLC25A1 axis

Authors:
- Shihong Liu
- Deping Zhang
- Li Chen
- Shangfang Gao
- Xiu Huang
View Affiliations

Affiliations: Department of Nuclear Medicine, The People's Hospital of Tong Liang District, Chongqing 402560, P.R. China, Department of Radiography, The People's Hospital of Tong Liang District, Chongqing 402560, P.R. China
Published online on: February 20, 2020 https://doi.org/10.3892/ol.2020.11418
Pages: 3071-3078
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNA BRM (lncBRM) was first identified in liver cancer stem cells and was reported to promote multiple cancer types. However, the function of lncBRM in papillary thyroid carcinoma (PTC) remains unclear. The primary focus of the present study was to determine the biological role of lncBRM in PTC. Reverse transcription‑quantitative PCR assays revealed that lncBRM was upregulated in PTC tissues and cells. Cell Counting Kit‑8, Transwell invasion and colony‑formation assays were performed to assess cell proliferation, invasion and migration, respectively. Furthermore, high expression of lncBRM was associated with poor overall survival time in patients with PTC. lncBRM knockout significantly suppressed cell proliferation, migration and invasion. lncBRM was predicted to bind to microRNA (miR)‑331‑3p and targets SLC25A1. Overexpression of miR‑331‑3p or inhibition of SLC25A1 resulted in significantly suppressed proliferation, migration and invasion of PTC cells. Rescue assays demonstrated that inhibition of miR‑331‑3p significantly abrogated the effects of lncBRM knockout on PTC cell proliferation, migration and invasion. In conclusion, the present study suggests that lncBRM promotes PTC by regulating miR‑331‑3p and targeting SLC25A1.

View Figures

View References

1	Chen C, Huang S, Huang A, Jia Y, Wang J, Mao M, Zhou J and Wang L: Total endoscopic thyroidectomy versus conventional open thyroidectomy in thyroid cancer: A systematic review and meta-analysis. Ther Clin Risk Manag. 14:2349–2361. 2018. View Article : Google Scholar : PubMed/NCBI
2	Huang F, Zhang Q, Chen W, Zhang H, Lu G, Chen J and Qiu C: Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway. J Cell Biochem. 120:10380–10390. 2019. View Article : Google Scholar : PubMed/NCBI
3	Liu J, Wang Y and Zhang B: Advances in diagnosis and treatment of thyroid cancer in children and adolescents. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 40:838–842. 2018.(In Chinese). PubMed/NCBI
4	Davis PJ, Tang HY, Hercbergs A, Lin HY, Keating KA and Mousa SA: Bioactivity of thyroid hormone analogs at cancer cells. Front Endocrinol (Lausanne). 9:7392018. View Article : Google Scholar : PubMed/NCBI
5	Albano D, Durmo R, Bertagna F and Giubbini R: 18F-choline PET/CT incidental thyroid uptake in patients studied for prostate cancer. Endocrine. 63:531–536. 2019. View Article : Google Scholar : PubMed/NCBI
6	Bolf EL, Sprague BL and Carr FE: A linkage between thyroid and breast cancer: A common etiology? Cancer Epidemiol Biomarkers Prev. 28:643–649. 2018. View Article : Google Scholar : PubMed/NCBI
7	Enokida T and Tahara M: I. genomic medicine in thyroid cancer. Gan To Kagaku Ryoho. 45:1711–1715. 2018.(In Japanese). PubMed/NCBI
8	Fu XM, Guo W, Li N, Liu HZ, Liu J, Qiu SQ, Zhang Q, Wang LC, Li F and Li CL: The expression and function of long noncoding RNA lncRNA-ATB in papillary thyroid cancer. Eur Rev Med Pharmacol Sci. 21:3239–3246. 2017.PubMed/NCBI
9	Guo Y, Zhang P, Sheng Q, Zhao S and Hackett TA: lncRNA expression in the auditory forebrain during postnatal development. Gene. 593:201–216. 2016. View Article : Google Scholar : PubMed/NCBI
10	Huang F, Chen W, Peng J, Li Y, Zhuang Y, Zhu Z, Shao C, Yang W, Yao H and Zhang S: lncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis. Mol Cancer. 17:982018. View Article : Google Scholar : PubMed/NCBI
11	Sun C, Luan S, Zhang G, Wang N, Shao H and Luan C: CEBPA-mediated upregulation of the lncRNA PLIN2 promotes the development of chronic myelogenous leukemia via the GSK3 and Wnt/β-catenin signaling pathways. Am J Cancer Res. 7:1054–1067. 2017.PubMed/NCBI
12	Ye B, Liu B, Yang L, Zhu X, Zhang D, Wu W, Zhu P, Wang Y, Wang S, Xia P, et al: lncKdm2b controls self-renewal of embryonic stem cells via activating expression of transcription factor Zbtb3. EMBO J. 37(pii): e971742018.PubMed/NCBI
13	Zheng JL, Sun J, Zhang H and Zhang Y: Role of microRNA and lncRNA in lens development and cataract formation. Zhonghua Yan Ke Za Zhi. 54:390–395. 2018.(In Chinese). PubMed/NCBI
14	Guo CJ, Zhang W and Gershwin ME: Long noncoding RNA lncKdm2b: A critical player in the maintenance of group 3 innate lymphoid cells. Cell Mol Immunol. 15:5–7. 2018. View Article : Google Scholar : PubMed/NCBI
15	Liu B, Ye B, Yang L, Zhu X, Huang G, Zhu P, Du Y, Wu J, Qin X, et al: Long noncoding RNA lncKdm2b is required for ILC3 maintenance by initiation of Zfp292 expression. Nat Immunol. 18:499–508. 2017. View Article : Google Scholar : PubMed/NCBI
16	Xiang Y, Huang Y, Sun H, Pan Y, Wu M and Zhang J: Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation. Biomed Pharmacother. 109:1630–1639. 2019. View Article : Google Scholar : PubMed/NCBI
17	Song Y, Zou L, Li J, Shen ZP, Cai YL and Wu XD: lncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 22:8161–8168. 2018.PubMed/NCBI
18	Yu Y, Shen HM, Fang DM, Meng QJ and Xin YH: lncRNA HCP5 promotes the development of cervical cancer by regulating MACC1 via suppression of microRNA-15a. Eur Rev Med Pharmacol Sci. 22:4812–4819. 2018.PubMed/NCBI
19	Jiang L, Wu Z, Meng X, Chu X, Huang H and Xu C: lncRNA HOXA-AS2 facilitates tumorigenesis and progression of papillary thyroid cancer through modulating miR-15a-5p/HOXA3 axis. Hum Gene Ther. 30:618–631. 2019. View Article : Google Scholar : PubMed/NCBI
20	Jiang W, Zhan H, Jiao Y, Li S and Gao W: A novel lncRNA-miRNA-mRNA network analysis identified the hub lncRNA RP11-159F24.1 in the pathogenesis of papillary thyroid cancer. Cancer Med. 7:6290–6298. 2018. View Article : Google Scholar : PubMed/NCBI
21	Wang XM, Liu Y, Fan YX, Liu Z, Yuan QL, Jia M, Geng ZS, Gu L and Lu XB: lncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther. 19:590–597. 2018. View Article : Google Scholar : PubMed/NCBI
22	Wu X, Yan Y, Li H, Ji N, Yu T, Huang Y, Shi W, Gao L, Ma L and Hu Y: DNA copy number gain-mediated lncRNA LINC01061 upregulation predicts poor prognosis and promotes papillary thyroid cancer progression. Biochem Biophys Res Commun. 503:1247–1253. 2018. View Article : Google Scholar : PubMed/NCBI
23	Gu Y, Feng C, Liu T, Zhang B and Yang L: The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer. PLoS One. 13:e02093382018. View Article : Google Scholar : PubMed/NCBI
24	Feng L, Yang B and Tang XD: Long noncoding RNA LINC00460 promotes carcinogenesis via sponging miR-613 in papillary thyroid carcinoma. J Cell Physiol. 234:11431–11439. 2019. View Article : Google Scholar : PubMed/NCBI
25	Zhang Y, Hu J, Zhou W and Gao H: lncRNA FOXD2-AS1 accelerates the papillary thyroid cancer progression through regulating the miR-485-5p/KLK7 axis. J Cell Biochem. Nov 19–2018.(Epub ahead of print). doi: 10.1002/jcb.28072.
26	Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B, Du Y, Gao G, Tian Y, He L and Fan Z: lncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. Nat Commun. 7:136082016. View Article : Google Scholar : PubMed/NCBI
27	Xi J, Feng J and Zeng S: Long noncoding RNA lncBRM facilitates the proliferation, migration and invasion of ovarian cancer cells via upregulation of Sox4. Am J Cancer Res. 7:2180–2189. 2017.PubMed/NCBI
28	Li R, Zhu H, Yang D, Xia J and Zheng Z: Long noncoding RNA lncBRM promotes proliferation and invasion of colorectal cancer by sponging miR-204-3p and upregulating TPT1. Biochem Biophys Res Commun. 508:1259–1263. 2019. View Article : Google Scholar : PubMed/NCBI
29	DeLellis RA and Williams ED: Tumours of the thyroid and parathyroid. World Health Organization Classification of Tumours. Pathology and Genetics of Endocrine Organs. IARC Press; Lyon: pp. 58–70. 2004
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Saini S, Maker AV, Burman KD and Prabhakar BS: Molecular aberrations and alterations in signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer. Biochim Biophys Acta Rev Cancer. Dec 31–2018.(Epub ahead of print). doi: 10.1016/j.bbcan.2018.12.003. PubMed/NCBI
32	Brajic A, Franckaert D, Burton O, Bornschein S, Calvanese AL, Demeyer S, Cools J, Dooley J, Schlenner S and Liston A: The Long Non-coding RNA Flatr Anticipates Foxp3 expression in regulatory T cells. Front Immunol. 9:19892018. View Article : Google Scholar : PubMed/NCBI
33	Xia F, Chen Y, Jiang B, Du X, Peng Y, Wang W, Huang W, Feng T and Li X: Long noncoding RNA HOXA-AS2 promotes papillary thyroid cancer progression by regulating miR-520c-3p/S100A4 pathway. Cell Physiol Biochem. 50:1659–1672. 2018. View Article : Google Scholar : PubMed/NCBI
34	Wang N, Duan H, Zhang C, Zhou Y and Gao R: The LINC01186 suppresses cell proliferation and invasion ability in papillary thyroid carcinoma. Oncol Lett. 16:5639–5644. 2018.PubMed/NCBI
35	Palmieri F: The mitochondrial transporter family SLC25: Identification, properties and physiopathology. Mol Aspects Med. 34:465–484. 2013. View Article : Google Scholar : PubMed/NCBI
36	Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, Kim KA, Riggins RB, Parasido E, Petrini I, et al: The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 25:1239–1258. 2018. View Article : Google Scholar : PubMed/NCBI
37	Bhalla K, Hwang BJ, Dewi RE, Ou L, Twaddel W, Fang HB, Vafai SB, Vazquez F, Puigserver P, Boros L and Girnun GD: PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res. 71:6888–6898. 2011. View Article : Google Scholar : PubMed/NCBI
38	Chi H, Yang R, Zheng X, Zhang L, Jiang R and Chen J: lncRNA RP11-79H23.3 functions as a competing endogenous RNA to regulate PTEN expression through sponging hsa-miR-107 in the development of bladder cancer. Int J Mol Sci. 19:25312018. View Article : Google Scholar
39	Cui S, Yang X, Zhang L, Zhao Y and Yan W: lncRNA MAFG-AS1 promotes the progression of colorectal cancer by sponging miR-147b and activation of NDUFA4. Biochem Biophys Res Commun. 506:251–258. 2018. View Article : Google Scholar : PubMed/NCBI
40	Hao Y, Yang X, Zhang D, Luo J and Chen R: Long noncoding RNA LINC01186, regulated by TGF-β/SMAD3, inhibits migration and invasion through Epithelial-Mesenchymal-Transition in lung cancer. Gene. 608:1–12. 2017. View Article : Google Scholar : PubMed/NCBI
41	Long J, Xiong J, Bai Y, Mao J, Lin J, Xu W, Zhang H, Chen S and Zhao H: Construction and Investigation of a lncRNA-associated ceRNA regulatory network in cholangiocarcinoma. Front Oncol. 9:6492019. View Article : Google Scholar : PubMed/NCBI